{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:03:33Z","timestamp":1781816613591,"version":"3.54.5"},"reference-count":37,"publisher":"Impact Journals, LLC","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,6,20]]},"DOI":"10.18632\/oncotarget.3614","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T06:31:06Z","timestamp":1442298666000},"page":"14905-14912","source":"Crossref","is-referenced-by-count":55,"title":["Human bone marrow niche chemoprotection mediated by cytochrome p450 enzymes"],"prefix":"10.18632","volume":"6","author":[{"given":"Salvador","family":"Alonso","sequence":"first","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Su","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jace W.","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudipto","family":"Ganguly","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen A.","family":"Kane","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Ghiaur","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,4,10]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/sj.leu.2402924","article-title":"Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms","volume":"17","author":"Dalton","year":"2003","journal-title":"Leukemia"},{"key":"2","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3109\/10428194.2011.576791","article-title":"Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression","volume":"52","author":"Qiu","year":"2011","journal-title":"Leukemia & lymphoma"},{"key":"3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0301-472X(01)00612-9","article-title":"Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5)","volume":"29","author":"Banker","year":"2001","journal-title":"Experimental hematology"},{"key":"4","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute myeloid leukaemia","volume":"368","author":"Dohner","year":"2006","journal-title":"Lancet"},{"key":"5","first-page":"7","article-title":"The hematopoietic stem cell niche\u2014home for friend and foe?","volume":"84","author":"Preffer","year":"2013","journal-title":"Cytometry Part B, Clinical cytometry"},{"key":"6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc2714","article-title":"Environment-mediated drug resistance: a major contributor to minimal residual disease","volume":"9","author":"Dalton","year":"2009","journal-title":"Nature reviews Cancer"},{"key":"7","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1158\/1078-0432.CCR-14-0900","article-title":"New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine","volume":"20","author":"Karp","year":"2014","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0092-8674(94)90212-7","article-title":"Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs","volume":"77","author":"te Riele","year":"1994","journal-title":"Cell"},{"key":"9","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1097\/00002030-200409240-00014","article-title":"Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men","volume":"18","author":"Rouzioux","year":"2004","journal-title":"Aids"},{"key":"10","doi-asserted-by":"crossref","first-page":"16121","DOI":"10.1073\/pnas.1305937110","article-title":"Regulation of human hematopoietic stem cell self-renewal by the microenvironment's control of retinoic acid signaling","volume":"110","author":"Jones","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/1097-4644(20010401)81:1<23::AID-JCB1021>3.0.CO;2-H","article-title":"Reciprocal control of osteoblast\/chondroblast and osteoblast\/adipocyte differentiation of multipotential clonal human marrow stromal F\/STRO-1(+) cells","volume":"81","author":"Marie","year":"2001","journal-title":"Journal of cellular biochemistry"},{"key":"12","doi-asserted-by":"crossref","first-page":"e6529","DOI":"10.1371\/journal.pone.0006529","article-title":"A versatile viral system for expression and depletion of proteins in mammalian cells","volume":"4","author":"Kaufman","year":"2009","journal-title":"PloS one"},{"key":"13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1021\/tx700079z","article-title":"Cytochrome p450 and chemical toxicology","volume":"21","author":"Guengerich","year":"2008","journal-title":"Chemical research in toxicology"},{"key":"14","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.bbagen.2006.09.016","article-title":"Mammalian cytochromes P450\u2014importance of tissue specificity","volume":"1770","author":"Rozman","year":"2007","journal-title":"Biochimica et biophysica acta"},{"key":"15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/09674845.2009.11730265","article-title":"Toxicity testing: the search for analternative to animal testing","volume":"66","author":"Donaldson","year":"2009","journal-title":"British journal of biomedical science"},{"key":"16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/138920006774832587","article-title":"Cytochrome P450 and anticancer drugs","volume":"7","author":"Fujita","year":"2006","journal-title":"Current drug metabolism"},{"key":"17","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood-2007-05-090258","article-title":"BiRD (Biaxin [clarithromycin]\/Revlimid [lenalidomide]\/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma","volume":"111","author":"Tepler","year":"2008","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ajh.21777","article-title":"Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma","volume":"85","author":"Fonseca","year":"2010","journal-title":"American journal of hematology"},{"key":"19","doi-asserted-by":"crossref","first-page":"E116","DOI":"10.1002\/ajh.23733","article-title":"Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma","volume":"89","author":"Huff","year":"2014","journal-title":"American journal of hematology"},{"key":"20","first-page":"2578","article-title":"Clarithromycin (Biaxin(R)) as primary treatment for myeloma","volume":"90","author":"Urnovitz","year":"1997","journal-title":"Blood"},{"key":"21","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood.V93.12.4441","article-title":"Lack of response to short-term use of clarithromycin (BIAXIN) in multiple myeloma","volume":"93","author":"Meharchand","year":"1999","journal-title":"Blood"},{"key":"22","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/sj.leu.2401332","article-title":"Lack of efficacy of clarithromycin in advanced multiple myeloma. Intergroupe Francais du Myelome (IFM)","volume":"13","author":"Harousseau","year":"1999","journal-title":"Leukemia"},{"key":"23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1046\/j.1365-2125.1997.54310.x","article-title":"The mechanism of cyclosporine toxicity induced by clarithromycin","volume":"43","author":"O'Connell","year":"1997","journal-title":"British journal of clinical pharmacology"},{"key":"24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1067\/mcp.2001.116511","article-title":"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide","volume":"70","author":"Kivisto","year":"2001","journal-title":"Clinical pharmacology and therapeutics"},{"key":"25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0022-3565(25)11065-3","article-title":"Human cytochrome P450 metabolism of teniposide and etoposide","volume":"261","author":"Nemec","year":"1992","journal-title":"The Journal of pharmacology and experimental therapeutics"},{"key":"26","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Johnston","year":"2013","journal-title":"Nature reviews Cancer"},{"key":"27","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/nm909","article-title":"Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia","volume":"9","author":"Niitsu","year":"2003","journal-title":"Nature medicine"},{"key":"28","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1182\/blood-2008-10-186668","article-title":"CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy","volume":"113","author":"Melhem","year":"2009","journal-title":"Blood"},{"key":"29","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-08-0314","article-title":"Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance","volume":"7","author":"Hazlehurst","year":"2008","journal-title":"Molecular cancer therapeutics"},{"key":"30","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0090-9556(24)02983-0","article-title":"Kinetics and regulation of cytochrome P450-mediated etoposide metabolism","volume":"32","author":"Blair","year":"2004","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"key":"31","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1124\/dmd.107.020255","article-title":"Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics","volume":"36","author":"Zhang","year":"2008","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"key":"32","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1124\/dmd.105.005710","article-title":"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib","volume":"33","author":"Gan","year":"2005","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"key":"33","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1158\/1078-0432.CCR-08-0411","article-title":"PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients","volume":"14","author":"Chowbay","year":"2008","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/pros.22748","article-title":"Vitamin D receptor agonist EB1089 is a potent regulator of prostatic \u201cintracrine\u201d metabolism","volume":"74","author":"Thompson","year":"2014","journal-title":"The Prostate"},{"key":"35","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.4161\/cbt.8.13.8696","article-title":"Regulation of drug resistance by human pregnane X receptor in breast cancer","volume":"8","author":"Nie","year":"2009","journal-title":"Cancer biology & therapy"},{"key":"36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00003088-200544040-00002","article-title":"Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism","volume":"44","author":"Rochat","year":"2005","journal-title":"Clinical pharmacokinetics"},{"key":"37","first-page":"3723","article-title":"Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB\/c mice","volume":"24","author":"Hibi","year":"2004","journal-title":"Anticancer research"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T17:02:15Z","timestamp":1748624535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,10]]},"references-count":37,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2015,6,20]]}},"alternative-id":["3614","25915157"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.3614","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,10]]}}}